Second-line chemotherapy and beyond for non-small-cell lung cancer.

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Platinum-based chemotherapy is now established in the treatment of all stages of lung cancer. Despite the benefits of therapy, the majority of patients treated for lung cancer will ultimately progress. Some will retain good performance status and be candidates for additional, tumor-directed treatment. Docetaxel and pemetrexed have documented activity in phase III trials in patients progressing after first-line, platinum-based therapy. Gefitinib has recently been approved for treatment of disease in the third line. Numerous other agents with diverse mechanisms are currently undergoing evaluation in this setting. This review evaluates the population eligible for such treatments and discusses recent trials in second and subsequent lines of therapy.

Original languageEnglish
Pages (from-to)373-378
Number of pages6
JournalClinical Advances in Hematology and Oncology
Issue number6
StatePublished - Jun 2004
Externally publishedYes


Dive into the research topics of 'Second-line chemotherapy and beyond for non-small-cell lung cancer.'. Together they form a unique fingerprint.

Cite this